NEXT GENERATION IMMUNO-ONCOLOGY

Illuminating non-responsive tumours for attack and destruction

Discover More

OUR SCIENCE

DEVELOPING NEXT GENERATION IMMUNOTHERAPIES THAT ILLUMINATE NON-RESPONSIVE TUMOURS FOR DESTRUCTION BY THE IMMUNE SYSTEM.

Current immunotherapy approaches target the minority of tumours that are visible to the immune system. By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer, increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients.

Find out more >

SITC Poster

Request a copy of Grey Wolf's poster presented at the SITC 2019 conference

Latest News

January 9, 2020

Grey Wolf completes £2.5 million Series A2 financing for development of therapies targeting ERAP2

Press Releases

November 8, 2019

Grey Wolf Wins Best Startup Biotech Company at the OBN Awards 2019

News

PROUDLY AWARDED